Intelos (CEO Kim Seon-tae) participated in the ‘6 International Advanced Medical Devices and Medical Industry Exhibition (KOAMEX 30)’ held at EXCO in Daegu for 7 days from Friday, June 2th to Sunday, July 3nd.
Intelos is a company that has accumulated expertise by researching and developing in vitro diagnostic technology since its establishment in 2019. The company has been releasing rapid antigen diagnostic kits such as COVID-19 as well as diagnostic kits for various diseases such as malaria, dengue fever, hepatitis B and C, and sexually transmitted diseases, and most of these products are achieving success mainly through exports. am.
At this exhibition, Intelos exhibited ‘MAUVE COVID-19 Ag’, a COVID-19 rapid antigen diagnostic kit that recently obtained domestic approval. This was introduced as an immunochromatography test kit to qualitatively detect ‘SARS-CoV-2’ antigen (nucleocapsid protein) in nasopharyngeal and oropharyngeal swabs.
Intellos’ product is characterized by the application of special nanobeads that detect infection in the sample at least 2 to up to 20 times more sensitively than other diagnostic kits. Intelros plans to overcome the disadvantages of entering the domestic diagnostic kit market relatively late by improving product completeness through new nanoparticle materials, which are rare in domestic companies’ diagnostic kit product lines.
Kim Seon-tae, CEO of Intelros, said, “Although we are a company with a short history, we have proven our diagnostic kit development technology in various ways in overseas markets over the past several years.” He added, “At this exhibition, we are looking for partners to cooperate in domestic distribution to expand our business in the diagnostic kit market.” “The goal is to expand our influence,” he said as the reason for participating in the exhibition.
He continued, “Our diagnostic kits have achieved notable export results in South American markets, including Ecuador, Colombia, and Peru, and Southeast Asian markets, including Vietnam, Bangladesh, Cambodia, and Thailand, and we have confirmed a good response from local customers.” He added, “Currently, we are exporting products to the Middle East. “We are making every effort to obtain local licenses with the goal of entering the European market,” he added.
In addition, Intelos plans to gradually advance its diagnostic kit-related technology and secure a product lineup that can respond to a wider range of diseases. Regarding this, CEO Kim said, “Our mid- to long-term goal is to grow into a company that can produce the most diverse diagnostic kits in Korea.” He added, “We are supplying Intelos diagnostic kits to more than 100 national hospitals and diagnostic laboratories around the world. “We will keep pushing forward until the day comes,” he said.
Meanwhile, the main exhibition items of ‘KOAMEX 2023’ hosted by Daegu Metropolitan City and K-MEDI Hub are as follows. △Diagnostic and diagnostic devices such as scanners, measuring devices, and imaging devices △Clinical and inspection devices △Surgical and recycling devices △Hospital facilities and emergency equipment △Medical devices, parts, and services △Pharmaceutical devices △Medical services, SW